Pulmonary Arterial Hypertension Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
EIGR | F | Eiger BioPharmaceuticals, Inc. | 0.00 | |
GILD | F | Gilead Sciences, Inc. | 0.30 | |
RVPH | F | Reviva Pharmaceuticals Holdings, Inc. | 0.00 | |
GYRE | F | Gyre Therapeutics, Inc. | 9.13 | |
GPCR | F | Structure Therapeutics Inc. | 1.30 | |
AVTE | F | Aerovate Therapeutics, Inc. | -1.19 | |
KROS | D | Keros Therapeutics, Inc. | 1.21 | |
CNTA | D | Centessa Pharmaceuticals plc | 6.28 | |
LQDA | D | Liquidia Technologies, Inc. | 0.08 | |
ASND | D | Ascendis Pharma A/S | -1.71 |
Related Industries: Biotechnology Drug Manufacturers - Major
Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
IHE | C | iShares U.S. Pharmaceutical ETF | 29.36 | |
MEDI | D | Harbor Health Care ETF | 26.21 | |
OZEM | D | Roundhill GLP-1 & Weight Loss ETF | 24.49 | |
MEDX | F | Horizon Kinetics Medical ETF | 19.84 | |
HDLB | C | ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B due September 30, 2044 | 18.54 |
Compare ETFs
- Pulmonary Arterial Hypertension
Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.
Recent Comments
- TraderMike on Market Recap for Tuesday, May 21, 2024
- CharmingMole371 on Market Recap for Tuesday, May 21, 2024
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
From the Blog
Featured Articles